TY - JOUR T1 - Seeing the light: Improving the usability of fluorescence-guided surgery by adding an optimized secondary light source JF - medRxiv DO - 10.1101/2020.03.09.20032359 SP - 2020.03.09.20032359 AU - Jonathan T. Elliott AU - Dennis J. Wirth AU - Scott C. Davis AU - Jonathan D. Olson AU - Nathan E. Simmons AU - Timothy C. Ryken AU - Keith D. Paulsen AU - David W. Roberts Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/12/2020.03.09.20032359.abstract N2 - Background Tumors that take up and metabolize 5-aminolevulinic acid (5-AlA) emit bright pink fluorescence when illuminated with blue light, aiding surgeons in identifying the margin of resection. The adoption of this method is hindered by the blue light illumination, which is too dim to safely operate under, and therefore, necessitates switching back and forth from white-light mode. This paper examines the addition of an optimized secondary illuminant adapter (SIA) to improve usability of blue-light mode without degrading tumor contrast.Methods We used color science methods to evaluate the color of the secondary illuminant and its impact on color rendering index (CRI) as well as the tumor-to-background color contrast (TBCC). A secondary illuminant adapter was built to provide 475-600 nm light the intensity of which can be controlled by the surgeon and was evaluated in two patients.Results Secondary illuminant color had opposing effects on color rendering index (CRI) and tumor to background color contrast (TBCC); providing surgeon control of intensity allows this trade-off to be balanced in real-time. Experience in two cases suggests additional visibility adds value.Conclusion The addition of a secondary illuminant may mitigate surgeon complaints that the operative field is too dark under the blue light illumination required for 5-ALA fluorescence guidance by providing improved CRI without completely sacrificing TBCC.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02191488Funding StatementExternal funding for this work was provided by NIH/NCI R00 CA190890 and NIH/NCI RO1 NS052274. The authors would also like to acknowledge internal funding support from the Dartmouth-Hitchcock Medical Center’s Department of Surgery and the Translational Engineering in Cancer Program at the Norris Cotton Cancer Center.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request, pending a data sharing agreement approved by the IRB. ER -